Most Recent Posts
Lisa Tharp of the Ohio State Grange has written an interesting piece printed in the Columbus (OH) Dispatch: Medicare Part D plan works just fine as it is. A key insight: "...competition has driven down costs dramatically. Work from the Medicare trustees shows that the national average monthly premium for a Part D plan this year is just $30, well under the $53 projected at the program's creation.
Ah, flu season will soon be upon us. I see my supermarket and local pharmacy signing people up for this year's flu shot. Here's a piece from one of my favorite nerd sites talking about this years' vaccine and why it is important to be vaccinated.
Last week, my colleague Grady Forrer wrote about non-communicable diseases, which are posing new and growing threats to the developing world, including countries like India.
Recently, we had the chance to speak with Mary Grealy, president of the Healthcare Leadership Council (HLC), about the Medicare prescription drug benefit. Grealy is also the co-chair of Medicare Today, a program intended to help seniors understand and enroll in Medicare Part D.
This week, an op-ed by John C. Lechleiter - the president, chairman and CEO of Eli Lilly and Company, one of PhRMA's member companies - highlighted what he calls "two success stories," one being the jobs supported in Indiana by the innovative life sciences sector there and the other being the "efficiency and satisfaction" associated with Medicare Part D, the prescription drug benefit.
Biotechnology medicines are developed through biological processes using living cells or organisms, rather than the traditional chemical synthesis approach. The biotechnology medicines in the new report "Biotechnology Medicines in Development," are targeting autoimmune diseases, cancer, cardiovascular diseases, diabetes, HIV/AIDS and other infectious diseases, psoriasis, Alzheimer's disease, Parkinson's disease, asthma, chronic obstructive pulmonary disease; hemophilia, glaucoma and many genetic disorders.